Ubrelvy Has Been Approved by the FDA for Acute Migraine Treatment
Michael Hemsworth — February 5, 2020 — Lifestyle
The Ubrelvy (ubrogepant tablets) from Allergan have been approved by the Food and Drug Administration (FDA) as an oral treatment for those who suffer with acute migraines with or without auras in adults. The treatment consists of recommended 50mg or 100mg doses that can be taken orally with a second dose that can be taken after two hours, if needed. The product comes as the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist, which will come as welcome news to those who suffer with acute migraines.
Ubrelvy is expected to launch in the first quarter of 2020 in specialized unit-dose packets that contain one tablet to streamline the ease of administration for patients.
Image Credit: MPR
Ubrelvy is expected to launch in the first quarter of 2020 in specialized unit-dose packets that contain one tablet to streamline the ease of administration for patients.
Image Credit: MPR
4.8
Score
Popularity
Activity
Freshness
